IP Library › Granted Patent US 10,980,822
Granted Patent B2
US 10,980,822 · App. 16/485,888 · Granted Apr 20, 2021

Medicinal composition comprising SGLT-2 inhibitor and angiotensin receptor blocker

Inventor: Tae-Hun Kim (Sejong, KR)
Assignee: AUTOTELIC BIO INC.
A61K31/70A61K31/4178A61P3/10A61P9/12A61K9/2018A61K9/2054
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,980,822
App. No.
16/485,888
Granted
Apr 20, 2021
Kind
B2
Abstract

Provided is a pharmaceutical composition comprising an antidiabetic agent and an antihypertensive agent as active ingredients.

Claims (7)

1. A pharmaceutical composition comprising comprising an effective amount of a sodium glucose cotransporter-2 (SGLT-2) inhibitor and an effective amount of an angiotensin receptor blocker to control blood pressure,

wherein the SGLT-2 inhibitor is dapagliflozin or a pharmaceutically acceptable salt or solvate thereof, and

wherein the angiotensin receptor blocker is olmesartan, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a composition for treating a disorder comprising hypertension.

3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a composition for treating a disorder comprising hypertension and diabetes.

4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is for administration to patients with a disorder comprising hypertension or patients with a disorder comprising both hypertension and diabetes.

5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a solid formulation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2019
From: KIM, TAE HUN
To: AUTOTELIC BIO INC.
Reel/Frame 050049/0102 →
Priority Claims (2)
KR 10-2017-0120311 · Sep 19, 2017 · national
KR 10-2018-0075025 · Jun 28, 2018 · national
Continuity (1)
Related Publication 20200054656A1 · Feb 20, 2020